Ferring Company Profile

What is the competitive landscape for FERRING

FERRING has seventeen approved drugs.

There are nineteen US patents protecting FERRING drugs.

There are two hundred and thirty-seven patent family members on FERRING drugs in thirty-five countries and twenty-two supplementary protection certificates in ten countries.

Summary for Ferring

International Patents:	237
US Patents:	19
Tradenames:	17
Ingredients:	8
NDAs:	17
Patent Litigation for Ferring:	See patent lawsuits for Ferring

Drugs and US Patents for Ferring

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ferring Pharms Inc	CLENPIQ	citric acid; magnesium oxide; sodium picosulfate	SOLUTION;ORAL	209589-001	Nov 28, 2017		RX	Yes	Yes	10,624,879		Y
Ferring Pharms Inc	DDAVP	desmopressin acetate	TABLET;ORAL	019955-002	Sep 6, 1995	AB	RX	Yes	Yes
Ferring	DESMOPRESSIN ACETATE	desmopressin acetate	TABLET;ORAL	021795-001	May 8, 2008		DISCN	No	No
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-002	Dec 24, 2008		RX	Yes	Yes	9,579,359
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-001	Dec 24, 2008		RX	Yes	No	10,729,739
Ferring Pharms Inc	NOCDURNA	desmopressin acetate	TABLET;SUBLINGUAL	022517-001	Jun 21, 2018		DISCN	Yes	No	11,963,995

Expired US Patents for Ferring

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ferring Pharms Inc	CERVIDIL	dinoprostone	INSERT, EXTENDED RELEASE;VAGINAL	020411-001	Mar 30, 1995	5,269,321
Ferring Pharms Inc	DDAVP	desmopressin acetate	TABLET;ORAL	019955-001	Sep 6, 1995	5,763,407
Ferring Pharms Inc	DDAVP	desmopressin acetate	TABLET;ORAL	019955-002	Sep 6, 1995	5,674,850
Ferring Pharms Inc	DDAVP	desmopressin acetate	INJECTABLE;INJECTION	018938-001	Mar 30, 1984	5,763,407
Ferring Pharms Inc	NOCDURNA	desmopressin acetate	TABLET;SUBLINGUAL	022517-002	Jun 21, 2018	8,802,624
Ferring Pharms Inc	NOCDURNA	desmopressin acetate	TABLET;SUBLINGUAL	022517-002	Jun 21, 2018	7,947,654

Paragraph IV (Patent) Challenges for FERRING drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Oral Solution	10 mg, 3.5 g, and12 g		2019-02-11
	Oral Solution	10 mg, 3.5 g, and 12 g		2014-05-21

International Patents for Ferring Drugs

Country	Patent Number	Estimated Expiration
Canada	2702152
European Patent Office	3120835
Japan	2014167001
Portugal	3225250
Russian Federation	2010133481
Taiwan	I549681

Supplementary Protection Certificates for Ferring Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2712622	122017000006	Germany		PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504
3225249	2019C/520	Belgium		PRODUCT NAME: DESMOPRESSINE OF EEN ACETAATZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE497271 - BE497280 20160513
2861072	2024C/512	Belgium		PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL, EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE (Y COMPRIS SOUS FORME HEMIHYDRATEE) ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210406
2782584	301153	Netherlands		PRODUCT NAME: COMPOSITION CONTAINING BOTH ESTRADIOL (17SS-ESTRADIOL), OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF (INCLUDING IN HEMIHYDRATE FORM), AND PROGESTERONE; NATIONAL REGISTRATION NO/DATE: RVG 125821 20210611; FIRST REGISTRATION: BE BE582231 20210406
2712622	LUC00015	Luxembourg		PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101
1003774	PA2009005,C1003774	Lithuania		PRODUCT NAME: DEGARELIXUM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001, 2009 02 17 EU/1/08/504/002 20090217

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Ferrante
• Ferrer Internacional
• Ferring
• Ferring Pharms Inc

Pharmaceutical Competitive Landscape Analysis: Ferring – Market Position, Strengths & Strategic Insights

In the dynamic world of pharmaceuticals, Ferring Pharmaceuticals stands out as a key player with a strong focus on innovation and research. This Swiss multinational biopharmaceutical company has carved a niche for itself in specialized areas such as reproductive health, maternal health, gastroenterology, and urology. Let's dive into Ferring's market position, strengths, and strategic insights to understand how this company is shaping the competitive landscape of the pharmaceutical industry.

Ferring's Market Position

Ferring has established a strong market position in the pharmaceutical industry, particularly in the field of reproductive medicine. The company's commitment to developing innovative treatments for mothers and babies over the past 50 years has solidified its reputation as a leader in this specialized area[1].

With operations in over 50 countries and products marketed in more than 100 countries, Ferring has a significant global presence[8]. This extensive reach allows the company to serve a diverse range of patients and adapt to regional differences in healthcare needs and regulations.

"Ferring Pharmaceuticals is a Swiss multinational biopharmaceutical company specialising in areas such as reproductive health, maternal health, gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years."[1]

Key Strengths and Competitive Advantages

1. Innovative Research and Development

Ferring's commitment to innovation is evident in its substantial investment in research and development. The company dedicates approximately 16% of its annual sales to R&D efforts[4]. This focus on innovation allows Ferring to stay at the forefront of medical advancements and maintain a competitive edge in the market.

2. Specialized Expertise

Ferring's specialization in reproductive medicine and maternal health sets it apart from many of its competitors. This focused approach has allowed the company to develop deep expertise and a strong reputation in these niche areas.

3. Global Presence

With R&D centers in 10 countries and manufacturing facilities in 12 countries, Ferring has a robust global infrastructure[8]. This extensive network enables the company to conduct research, manufacture products, and distribute them efficiently across various markets.

4. Strong Product Pipeline

Ferring maintains a robust pipeline of products in various stages of development. This diverse portfolio ensures a steady stream of new treatments and therapies, addressing a wide range of reproductive health issues and other specialized areas[3].

Strategic Initiatives and Growth Strategy

1. Expansion into Emerging Markets

Ferring is actively pursuing opportunities in emerging markets where there is growing demand for reproductive medicine and healthcare solutions. This expansion strategy allows the company to tap into new sources of revenue and establish itself as a global leader in the industry[3].

2. Focus on Digital Transformation

Embracing digital technologies and data analytics is a key part of Ferring's strategy to improve operational efficiency, enhance patient outcomes, and drive innovation in the healthcare sector[3].

3. Strategic Partnerships and Acquisitions

Ferring has been actively engaging in strategic partnerships and acquisitions to enhance its capabilities and expand its product offerings. For example, in 2018, the company acquired Rebiotix Inc., a biotechnology company specializing in microbiome therapeutics[1].

Recent Performance and Future Outlook

Ferring has shown strong financial performance in recent years. In 2021, the company reported record results with revenues of €2,162 million, representing an 11% increase at actual exchange rates (AER) and a 14% increase at constant exchange rates (CER)[5].

Looking ahead, Ferring aims to grow its sales at an average annual rate of 10% to reach the €3 billion mark by 2020[4]. The company's focus on innovation, strategic partnerships, and expansion into new markets positions it well for future growth and success in the competitive pharmaceutical landscape.

Challenges and Opportunities

Challenges

1. Regulatory Hurdles: Navigating the complex regulatory landscape in the healthcare sector remains a significant challenge for Ferring[6].

2. Competition: The company faces stiff competition from other pharmaceutical giants in its specialized areas[6].

3. Pricing Pressures: Increasing pressure to control healthcare costs could impact Ferring's pricing strategy for its products[6].

Opportunities

1. Expansion into Emerging Markets: There is significant potential for growth in emerging markets with increasing demand for reproductive medicine[3].

2. Digital Health Solutions: Leveraging digital technologies can help Ferring improve patient outcomes and operational efficiency[3].

3. Personalized Medicine: The trend towards personalized medicine presents opportunities for Ferring to develop more targeted therapies[3].

Industry Trends Shaping Ferring's Strategy

The pharmaceutical industry is constantly evolving, and several key trends are shaping Ferring's strategy:

1. Personalized Medicine: The shift towards tailored treatments based on individual patient characteristics is driving innovation in drug development.

2. Digital Health: The integration of digital technologies in healthcare is transforming patient care and drug development processes.

3. Sustainability: Increasing focus on environmental, social, and governance (ESG) factors is influencing pharmaceutical companies' operations and strategies.

4. Microbiome Research: Growing understanding of the human microbiome is opening up new avenues for treatment, particularly relevant to Ferring's gastroenterology focus.

Key Takeaways

• Ferring Pharmaceuticals has established a strong market position in specialized areas such as reproductive health and maternal health.
• The company's focus on innovation, global presence, and strategic partnerships are key strengths driving its competitive advantage.
• Ferring's robust product pipeline and expansion into emerging markets position it well for future growth.
• While facing challenges such as regulatory hurdles and pricing pressures, Ferring also has significant opportunities in digital health solutions and personalized medicine.
• The company's recent financial performance has been strong, with record results reported in 2021.

FAQs

1. What are Ferring's main therapeutic areas? Ferring specializes in reproductive medicine, maternal health, gastroenterology, and urology.

2. How much does Ferring invest in research and development? Ferring invests approximately 16% of its annual sales in R&D efforts.

3. What was Ferring's revenue in 2021? In 2021, Ferring reported revenues of €2,162 million.

4. Where is Ferring headquartered? Ferring is headquartered in Saint-Prex, Switzerland.

5. What recent acquisition has Ferring made in the field of microbiome therapeutics? In 2018, Ferring acquired Rebiotix Inc., a biotechnology company specializing in microbiome therapeutics.

Sources cited: [1] https://en.wikipedia.org/wiki/Ferring_Pharmaceuticals [3] https://canvasbusinessmodel.com/blogs/growth-strategy/ferring-growth-strategy [4] https://www.pharmexec.com/view/quiet-company [5] https://www.ferring.com/ferring-delivered-record-results-in-2021-and-is-on-course-for-future-ambitions/ [6] https://canvasbusinessmodel.com/blogs/competitors/ferring-competitive-landscape [8] https://master-3.corporate.ferring.tech/about-ferring/ferring-group-of-companies/our-global-presence/